Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Trogenix has developed a platform for generating ‘synthetic super-enhancers’ that could drive highly cell-specific gene therapy-based treatment of solid tumors such as glioblastoma.